Is adjuvant radiotherapy necessary for FIGO stage 1a grade 2 endometrial endometrioid adenocarcinoma?

Basit Öğe Kaydı
dc.contributor.authorInan, Abdurrahman Hamdi
dc.contributor.authorErsoy, Gulcin Sahin
dc.contributor.authorYildinm, Yusuf
dc.contributor.authorGurbuz, Tutku
dc.contributor.authorKebapcilar, Ayse Gul
dc.contributor.authorHanhan, Merih
dc.date.accessioned2020-03-26T19:06:13Z
dc.date.available2020-03-26T19:06:13Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjective: The impact of adjuvant radiotherapy on the rates of survival and local recurrence was analyzed in patients diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage 1a grade 2 endometrial endometrioid adenocarcinoma. Material and Methods: Medical records of 82 patients diagnosed and treated for FIGO stage 1a grade 2 endometrial endometrioid adenocarcinoma were reviewed retrospectively. A group of 59 patients who received postoperative radiotherapy was compared with a control group of 23 subjects treated without adjuvant radiotherapy; the duration of survival as well as the local recurrence and metastasis rates were evaluated in both groups. Results: The analysis of patient data has revealed the rate of local recurrence as 4.3% vs. 1.7% (p=0.485), the rate of distant metastasis as 4.3% vs. 6.9% (p=1.000), and the mean survival time as 83.6 +/- 38.7 vs. 81.5 +/- 37.5 months (p=0.828) in the adjuvant radiotherapy and control groups, respectively. Conclusion: In the presented study, adjuvant radiotherapy failed to improve the overall survival of the patients in the low-risk group (stage 1a grade 2). With the addition of the significant risk of radiation toxicity, it is highly probable that these patients will not benefit from postoperative radiotherapy. Close observation should be performed following the primary surgery in this patient group. Nevertheless, it should also be considered that adjuvant radiotherapy is a very effective treatment modality for the recovery of patients with vaginal relapse.en_US
dc.identifier.doi10.5152/jtgga.2015.15163en_US
dc.identifier.endpage157en_US
dc.identifier.issn1309-0399en_US
dc.identifier.issn1309-0380en_US
dc.identifier.issue3en_US
dc.identifier.pmid26401108en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage153en_US
dc.identifier.urihttps://dx.doi.org/10.5152/jtgga.2015.15163
dc.identifier.urihttps://hdl.handle.net/20.500.12395/32272
dc.identifier.volume16en_US
dc.identifier.wosWOS:000360154900005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTURGUT YAYINCILIK & TICARET ASen_US
dc.relation.ispartofJOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATIONen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectEndometrial canceren_US
dc.subjectadjuvant radiotherapyen_US
dc.subjectmean survival timeen_US
dc.titleIs adjuvant radiotherapy necessary for FIGO stage 1a grade 2 endometrial endometrioid adenocarcinoma?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu